AJCP / Meeting AbstrActs (PNP) has been a key part of the diagnostic approach for patients who present with neurological symptoms of undetermined etiology, especially those with cancer or risk factors for cancer. Like other costly, complex tests, it presents a good template for utilization optimization. Many reports have been written on the utility of PNP testing in specific diseases (eg, motor neuron disease). However, the literature is scant on the use and utilization of the PNP for an entire hospital. Methods: We performed a one-year retrospective chart review of all PNP orders, in a 700-bed academic tertiary center in the Eastern United States. For all orders, we determined if there was a positive finding, and if appropriate clinical actions were taken in response to the results. Results: A total of 248 samples were sent out for PNP evaluation. The cost per test panel was $871. Of the 248 samples, 27(10.8%) had a positive finding. Six of the 27 (22.2%) had a history of malignancy (pituitary adenoma, thymic carcinoma [2], prostate adenocarcinoma, renal cell carcinoma, and squamous cell carcinoma of the tongue). Nine different autoantibodies were detected. Fifteen of the 27 (55.5%) cases were deemed to have appropriate clinical follow-up. Seven of the 27 (25.9 %, 2.8% overall) led to further action by the clinical team. Conclusions: Our expert clinicians who ordered PNP tests obtained a positive result in 11% of patients. This positivity rate suggests that the patients were appropriately selected for testing. However, in the three-quarters of patients with positive results and no history of malignancy, there was no subsequent referral to attempt to diagnose a neoplasm. These patients represent a group where appropriate response to laboratory results could improve test utility and save costs. In addition, these results can be used for comparison and to help establish utilization guidelines for PNP testing at other institutions.
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Computerized Approach to Antibody Identification in Pretransfusion Testing
Reyhan Gedik, Michael Vonplato, Karen Quillen; Boston Medical Center, Boston, MA Background: Antibody screening and identification are key components of pre-transfusion compatibility testing.
Patient's plasma is tested against one or more panels of reagent red blood cells with known antigen phenotype. Pathology residents and lab technologists use a "crossout" method to identify the patient's allo-antibody(ies), based on the pattern of reaction of patient's plasma with the reagent cells. Manual interpretation is time-consuming, and prone to human error. Methods: We designed a spreadsheet to automate the enumeration and dosage of "rule-out" cells, non-reactive with the patient's plasma. An antigen is completely ruled out if two homozygous cells, or one homozygous and two heterozygous cells expressing a particular antigen are non-reactive with patient's plasma. An antigen specificity is "ruled in" when it is not ruled out, and when it explains two to three positive reactions (between patient plasma and reagent cells). For rule-outs that are incomplete, the number of additional cells needed is indicated. Results: We validated our spreadsheet on 25 panels with 100% concordance compared to the manual approach. Antibody specificities identified included anti-D, E, e, C, c, K, Fy(a), Jk(a), Jk(b), M and S. With this method, preliminary antibody interpretation takes less than one minute per case. Limitations of this approach include the lack of consideration of reaction strength (1+ vs 4+), and the need to enter the phenotypes of each new lot of panel cells. An example spreadsheet can be viewed at https:// goo.gl/TpKoyn. Conclusion: A computerized approach to antibody identification reduces time spent on manual cross-outs, reduces human error, and simplifies the initial steps of teaching antibody identification to pathology residents and medical technologists.
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A Comparison of Urinary Cell Cycle Markers of Acute Kidney Injury ([IGFBP7]*[TIMP2]) and the Product of Classic Urinary Markers [Albumin]*[Creatinine]
Rajeevan Selvaratnam, Beth Stodardt, Ashlinn Milligan; BayCare Health System, Clearwater, FL To evaluate the urinary tissue inhibitor ofmetalloproteinases-2 (TIMP2) and insulin-like growth factor binding protein 7 (IGFBP7) as markers of acute kidney injury (AKI). The test, approved and marketed as Nephrocheck measures both cell cycle biomarkers with the results reported as a product of the two measurement and normalized by 1,000 (ie, [TIMP2] [IGFBP7]/1,000). Several biomarkers for AKI have been proposed in the past, including NGAL, KIM, cystatin, and urinary albumin. However, Nephrocheck is a test that employs a multimarker approach to assessing AKI. Therefore, our goal was to evaluate also the product of two classical markers (urinary albumin and urinary creatinine) normalized by a factor of 1,000 (PACU), ie, (ALBUMIN) (Creatinine)/1,000. PACU, or product of urinary albumin and urinary creatinine, was normalized by a factor of 1,000 for comparative purposes with Nephrocheck. Although creatinine is often used to normalize albumin in urine (ie, albumin:creatinine ratio [ACR]), we reasoned that urine creatinine is also a measure of kidney injury and in a multimarker approach would hypothetically enhance the overall predictive power of AKI. To evaluate the utility of PACU and Nephrocheck, we evaluated 16 patients subject to Nephrochec test, based on the
